

(CIN:L24232GJ1996PLC029894)



Date: 29 August 2023

Ref. No.: TCPCL/SEC/2023-24/00058

To,

The General Manager, Corporate relationship department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001 Scrip Code: 543321

The Manager, Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra-Kurla, Complex Bandra(E), Mumbai-400 051 Scrip Symbol: TATVA

- Sub: Disclosure of the details of allotment in the Issue (as defined hereinafter) by Tatva Chintan Pharma Chem Limited (the "Company") in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements), 2015, as amended (the "SEBI Listing Regulations").
- Re: Qualified institutions placement of equity shares of face value of ₹ 10 each (the "Equity Shares") by Tatva Chintan Pharma Chem Limited (the "Company") under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations"), and Sections 42 and 62 of the Companies Act, 2013 (including the rules made thereunder), as amended (the "Issue").

Dear Sir/Madam,

In continuation of our earlier letter dated 29 August 2023, on the captioned subject, we wish to inform you that, in respect of the Issue, the Fund Raising Committee of Directors ("**Committee**") at its Meeting held today, i.e., 29 August 2023, has inter alia, approved the issue and allotment of 12,26,993 Equity Shares to 9 qualified institutional buyers at the issue price of ₹ 1,630 per Equity Share i.e. at a premium of ₹ 1,620 per Equity Share, which reflects a discount of ₹ 74.74 (i.e. 4.38%) on the floor price of ₹ 1,704.74 calculated with reference to the relevant date of 24 August 2023, aggregating to ₹ 1,99,99,98,590 (One Hundred and Ninety-Nine Crore Ninety-Nine Lakh Ninety-Eight Thousand Five hundred and Ninety Only), pursuant to the Issue in accordance with the provisions of the SEBI ICDR Regulations.

Pursuant to the allotment of Equity Shares in the Issue, the paid-up Equity Share capital of the Company stands increased from ₹ 22,16,50,620 consisting of 2,21,65,062 Equity Shares to ₹ 23,39,20,550 consisting of 2,33,92,055 Equity Shares.

Further, find attached herewith the list of allottees who have been allotted more than 5% of the Equity Shares offered in the Issue, marked as **Annexure 1**.

The Issue opened on 24 August 2023 and closed on 29 August 2023 and the same was intimated to you through our letters dated 24 August 2023 and 29 August 2023, respectively.

The meeting of the Committee commenced at 10.50 p.m. (IST) and concluded at 11.00 p.m. (IST).

Registered Office and Factory: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.
Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.
Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. : +91 75748 48533 / 34 Fax : +91 265 263 8533 E-mail : cs@tatvachintan.com Website : www.tatvachintan.com



(CIN:L24232GJ1996PLC029894)



We request you to kindly take this on records, and the same be treated as compliance under the applicable regulations of the Securities and Exchange Board of India (Listing Obligations Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully, For Tatva Chintan Pharma Chem Limited

Ishwar Nayi Company Secretary and Compliance Officer M. No.: A37444

Encl.: Annexure 1

Registered Office and Factory: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.
Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.
Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. : +91 75748 48533 / 34 Fax : +91 265 263 8533 E-mail : cs@tatvachintan.com Website : www.tatvachintan.com



(CIN:L24232GJ1996PLC029894)



Annexure 1

List of Allottees who have been allotted more than 5% of the Equity Shares offered in the Issue

Sr. No.	Name of the Allottees	No. of Equity Shares Allotted	% of total Issue size	
1.	GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO	2,14,723	17.50%	17.50%
2.	NIPPON LIFE INDIA TRUSTEE LTD -A/C NIPPON INDIA SMALL CAP FUND	2,60,738	21.25%	42.5%
3.	NIPPON LIFE INDIA TRUSTEE LTD -A/C NIPPON INDIA TAX SAVER (ELSS) FUND	2,60,738	21.25%	42.370
4.	ICICI PRUDENTIAL SMALLCAP FUND	3,12,116	25.44%	37%
5.	ICICI PRUDENTIAL MNC FUND	85,123	6.94%	
6.	ICICI PRUDENTIAL COMMODITIES FUND	56748	4.62%	

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi Company Secretary and Compliance Officer M. No.: A37444

Registered Office and Factory: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.
Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.
Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. : +91 75748 48533 / 34 Fax : +91 265 263 8533 E-mail : cs@tatvachintan.com Website : www.tatvachintan.com